


JNJ-54175446

Chemical Properties

CAS No. : 1627902-21-9
 Formula: C₁₈H₁₃ClF₄N₆O
 Molecular Weight: 440.78
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	JNJ-54175446 (JNJ-5446) is a CNS-permeable and selective P2X7 receptor antagonist that attenuates the release of IL-1 β /IL-18 from microglia, and may be used in the study of depression.
Targets(IC50)	P2X Receptor
In vitro	JNJ-54175446 is a selective purinergic P2X7 receptor (P2X7R) antagonist that attenuates the release of IL-1 β /IL-18 from microglial cells[1].
In vivo	JNJ-54175446 (30 mg/kg, intraperitoneal) administered once daily significantly reduces spontaneous recurrent seizures in mice, persisting for several days after the end of treatment[1].

Solubility Information

Solubility	DMSO: 50 mg/mL (113.44 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.54 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2687 mL	11.3435 mL	22.6871 mL
5 mM	0.4537 mL	2.2687 mL	4.5374 mL
10 mM	0.2269 mL	1.1344 mL	2.2687 mL
50 mM	0.0454 mL	0.2269 mL	0.4537 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Letavic MA, et al. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. Send to

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481